Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Asia Pacific is expected to be the fastest regional market for asthma and COPD devices owing to the increased incidence of asthma & other respiratory diseases in industrial regions. The Asia Pacific market for Asthma & COPD has been analyzed on the basis of drugs and devices used for these diseases.
Key drugs employed for control and diagnosis of asthma and COPD may be classified on the basis of their types which include bronchodilators, leukotriene antagonists, mast cell stabilizers and immunosuppressants. Degrading air quality near the industrial areas has led to the increased incidence of asthma especially in the low-income population in the emerging economies.
Increasing disposable income levels in emerging economies as well as developing countries have led to the increased usage of asthma pumps and sprays in these regions. The report highlights the adoption of COPD & Asthma Devices in the Asia Pacific. Based on the product type;
the market is segmented into Inhalers and Nebulizers market. Further, the Inhaler segment is sub-segmented into Dry Powder Inhalers, Metered Dose Inhalers and Soft Mist Inhalers Market. The Nebulizers segment is bifurcated into Pneumatic Nebulizers, Ultrasonic Nebulizers, and Mesh Nebulizers Market.
The countries included in the report are Germany, UK, France, Russia, Spain, Italy and Rest of Asia Pacific. Key players profiled in the report include Glaxosmithcline PLC., Novartis International AG., Biotronik SE & Co. KG., AstraZeneca Plc., 3M Healthcare, GF Health Products, Inc., Sunovion Pharmaceuticals Inc., Smith Medicals, Inc., Baxter International and Philips.